There is an increasing indication of bariatric surgery for metabolic diseases irrespective of body weight. Diabetic retinopathy is a serious disease; it is the leading cause of registered visual loss globally. Previous literature reported the deterioration of lifethreatening diabetic retinopathy after bariatric surgery. Few studies assessed the same. Our aim of the study is to assess this metaanalysis for the effects of bariatric surgery on diabetic retinopathy remission. In addition, we assessed the effects of bariatric surgery on diabetic retinopathy deterioration. We systematically searched PubMed, Cochrane Library, and the first 100 articles in Google Scholar. The search engine was limited to articles published in English from the first published article up to June 2022. The following keywords were used, bariatric surgery, metabolic surgery, diabetic retinopathy, retinopathy remission, and retinopathy deterioration. The retrieved data were entered in a datasheet detailing the author's name, year and country of publication, the methodology, and the number of patients who deteriorated was stable or improved after bariatric surgery. The most recent RevMan (version 4.4.) was used for data analysis. From our study, we found that, out of the 386 studies screened, only 26 full texts were eligible and eleven studies fulfilled the inclusion and exclusion criteria. A lower deterioration rate was observed than stability, odd ratio, 0.05, 95% CI, 0.04-0.07, P-value, <0.001. Significant heterogeneity was observed, I2=54%, P-value, 0.02, and Chi-square=21.76. in addition, a lower regression was found compared to stable retinopathy, odd ratio, 0.06, 95% CI, 0.03-0.13, P-value, <0.001. Significant heterogeneity was observed, I2=73%, P-value, 0.0002, and Chi-square=29.67. Thus, Diabetic retinopathy remains stable among patients who underwent bariatric surgery. Few remissions were observed in the short term, while few patients deteriorated. Further randomized controlled studies comparing the effect of bariatric surgery and usual diabetic care are needed.
Neovascular glaucoma (NVG) is an aggressive type of glaucoma, which often results in poor visual outcomes. Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia. Bevacizumab is a humanized anti-VEGF monoclonal IgG1 antibody. The potential of antivascular endothelial growth factor (anti-VEGF) agents to modify the disease course of neovascular glaucoma (NVG) was recognized shortly after their use in the treatment of age-related macular degeneration was reported. These medications were noted to induce rapid regression of the anterior segment neovascularization that characterizes NVG. Several studies as well as extensive clinical experience have demonstrated a rapid regression of anterior segment neovascularization following the injection of anti-VEGF agents. This review aims to summarize current evidences regarding effectiveness of Bevacizumab in management of neovascular glaucoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.